Daewoong Pharmaceutical To In-license Almirall's COPD drug Eklira In Korea
This article was originally published in PharmAsia News
Daewoong signs in-licensing deal just one week before Eklira – a product with a history of clinical setbacks – faces U.S. FDA advisory committee meeting.
You may also be interested in...
SEOUL - Daewoong Pharmaceutical has beefed up its product lineup and increased R&D investment for high-growth therapeutic areas, which has brightened the company's outlook in the eyes of some Korean analysts despite stronger generics competition in 2011
Forest Laboratories and Spain's Almirall report positive late-stage data for their COPD drug, paving the way for 2011 regulatory filings in the U.S. and EU.
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.